Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin

Felix Oh,1 Deborah Todhunter,1 Elizabeth Taras,1 Daniel A Vallera,1,2 Antonella Borgatti2,3 1Department of Therapeutic Radiology-Radiation Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Animal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Pau...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oh F, Todhunter D, Taras E, Vallera DA, Borgatti A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Sarcoma carcinoma eBAT EGFR uPAR Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4316ff848881453dbef3dc18798412cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4316ff848881453dbef3dc18798412cc
record_format	dspace
spelling	oai:doaj.org-article:4316ff848881453dbef3dc18798412cc2021-12-02T07:07:51ZTargeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin1179-1438https://doaj.org/article/4316ff848881453dbef3dc18798412cc2018-09-01T00:00:00Zhttps://www.dovepress.com/targeting-egfr-and-upar-on-human-rhabdomyosarcoma-osteosarcoma-and-ova-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Felix Oh,1 Deborah Todhunter,1 Elizabeth Taras,1 Daniel A Vallera,1,2 Antonella Borgatti2,3 1Department of Therapeutic Radiology-Radiation Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Animal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, MN, USA; 3Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA Purpose: Human sarcomas are rare and difficult to treat cancerous tumors typically arising from soft tissue or bone. Conversely, carcinomas are the most common cancer subtype in humans and the primary cause of mortality across all cancer patients. While conventional therapeutic modalities can prolong disease-free intervals and survival in some cases, treatment of refractory or recurrent solid tumors is challenging, and tumor-related mortality remains unacceptably high. The identification of overexpressed cell surface receptors on sarcoma and carcinoma cells has provided a valuable tool to develop targeted toxins as an alternative anticancer strategy. Recent investigation of recombinant protein-linked toxins that specifically target these cancer receptors has led to the development of highly specific, cytotoxic, and deimmunized drugs that can kill cancer cells. Methods: This study investigated a recombinant protein called epidermal growth factor bispecific angiotoxin (eBAT), which is designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the urokinase plasminogen activator receptor (uPAR) on cancer cells and associated tumor vasculature. Both receptors are expressed by a variety of human sarcomas and carcinomas. Flow cytometry techniques were used to determine binding affinity of eBAT to cancer cells, and proliferation assays were performed to calculate tumor killing ability based on half-maximal inhibitory concentrations. Results: eBAT demonstrated cytotoxicity against a variety of sarcoma and carcinoma cells that overexpress EGFR and uPAR in vitro and showed greater cell killing ability and binding affinity to cancer cells compared with its monospecific counterparts. Conclusion: The results of our study are promising, and further studies will be necessary to confirm the applicability of eBAT as a supplementary therapy for a variety of sarcomas, carcinomas, and possibly other refractory malignancies that express EGFR and uPAR. Keywords: sarcoma, carcinoma, eBAT, EGFR, uPAROh FTodhunter DTaras EVallera DABorgatti ADove Medical PressarticleSarcomacarcinomaeBATEGFRuPARTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 113-121 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sarcoma carcinoma eBAT EGFR uPAR Therapeutics. Pharmacology RM1-950
spellingShingle	Sarcoma carcinoma eBAT EGFR uPAR Therapeutics. Pharmacology RM1-950 Oh F Todhunter D Taras E Vallera DA Borgatti A Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
description	Felix Oh,1 Deborah Todhunter,1 Elizabeth Taras,1 Daniel A Vallera,1,2 Antonella Borgatti2,3 1Department of Therapeutic Radiology-Radiation Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Animal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, MN, USA; 3Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA Purpose: Human sarcomas are rare and difficult to treat cancerous tumors typically arising from soft tissue or bone. Conversely, carcinomas are the most common cancer subtype in humans and the primary cause of mortality across all cancer patients. While conventional therapeutic modalities can prolong disease-free intervals and survival in some cases, treatment of refractory or recurrent solid tumors is challenging, and tumor-related mortality remains unacceptably high. The identification of overexpressed cell surface receptors on sarcoma and carcinoma cells has provided a valuable tool to develop targeted toxins as an alternative anticancer strategy. Recent investigation of recombinant protein-linked toxins that specifically target these cancer receptors has led to the development of highly specific, cytotoxic, and deimmunized drugs that can kill cancer cells. Methods: This study investigated a recombinant protein called epidermal growth factor bispecific angiotoxin (eBAT), which is designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the urokinase plasminogen activator receptor (uPAR) on cancer cells and associated tumor vasculature. Both receptors are expressed by a variety of human sarcomas and carcinomas. Flow cytometry techniques were used to determine binding affinity of eBAT to cancer cells, and proliferation assays were performed to calculate tumor killing ability based on half-maximal inhibitory concentrations. Results: eBAT demonstrated cytotoxicity against a variety of sarcoma and carcinoma cells that overexpress EGFR and uPAR in vitro and showed greater cell killing ability and binding affinity to cancer cells compared with its monospecific counterparts. Conclusion: The results of our study are promising, and further studies will be necessary to confirm the applicability of eBAT as a supplementary therapy for a variety of sarcomas, carcinomas, and possibly other refractory malignancies that express EGFR and uPAR. Keywords: sarcoma, carcinoma, eBAT, EGFR, uPAR
format	article
author	Oh F Todhunter D Taras E Vallera DA Borgatti A
author_facet	Oh F Todhunter D Taras E Vallera DA Borgatti A
author_sort	Oh F
title	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
title_short	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
title_full	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
title_fullStr	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
title_full_unstemmed	Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
title_sort	targeting egfr and upar on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/4316ff848881453dbef3dc18798412cc
work_keys_str_mv	AT ohf targetingegfranduparonhumanrhabdomyosarcomaosteosarcomaandovarianadenocarcinomawithabispecificliganddirectedtoxin AT todhunterd targetingegfranduparonhumanrhabdomyosarcomaosteosarcomaandovarianadenocarcinomawithabispecificliganddirectedtoxin AT tarase targetingegfranduparonhumanrhabdomyosarcomaosteosarcomaandovarianadenocarcinomawithabispecificliganddirectedtoxin AT vallerada targetingegfranduparonhumanrhabdomyosarcomaosteosarcomaandovarianadenocarcinomawithabispecificliganddirectedtoxin AT borgattia targetingegfranduparonhumanrhabdomyosarcomaosteosarcomaandovarianadenocarcinomawithabispecificliganddirectedtoxin
_version_	1718399565831340032

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin

Ejemplares similares